TEVA Pharmaceuticals submits ANDA219413 for FDA review
The submission of ANDA219413 by TEVA Pharmaceuticals is significant as it represents a potential entry of a generic product into the market. This could alter pricing dynamics and competitive positioning within the relevant therapeutic area, which is currently unspecified.
Company
TEVA PHARMACEUTICALS, INC
Asset
ANDA219413
Indication
Not specified
Status
Approved
Signal Score
6.8
Signal assessment
Signal strength
moderate
Confidence level
moderate
Strategic implication
The submission of ANDA219413 by TEVA Pharmaceuticals is significant as it represents a potential entry of a generic product into the market. This could alter pricing dynamics and competitive positioning within the relevant therapeutic area, which is currently unspecified.
Why it matters
The submission of ANDA219413 by TEVA Pharmaceuticals is significant as it represents a potential entry of a generic product into the market. This could alter pricing dynamics and competitive positioning within the relevant therapeutic area, which is currently unspecified.
What changed
Regulatory Approval
Analysis
TEVA Pharmaceuticals has submitted ANDA219413 to the FDA with a standard review priority.
The submission of ANDA219413 by TEVA Pharmaceuticals is significant as it represents a potential entry of a generic product into the market. This could alter pricing dynamics and competitive positioning within the relevant therapeutic area, which is currently unspecified.
Monitor the FDA's review timeline and any subsequent approval announcements for ANDA219413.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.